Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms DuoBody-CD3x5T4, GEN 1044 |
Target |
Mechanism 5T4 modulators(Trophoblast glycoprotein modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 2 | US | 15 Jul 2020 | |
Bladder Cancer | Phase 2 | DK | 15 Jul 2020 | |
Bladder Cancer | Phase 2 | IL | 15 Jul 2020 | |
Bladder Cancer | Phase 2 | ES | 15 Jul 2020 | |
Esophageal Carcinoma | Phase 2 | US | 15 Jul 2020 | |
Esophageal Carcinoma | Phase 2 | DK | 15 Jul 2020 | |
Esophageal Carcinoma | Phase 2 | IL | 15 Jul 2020 | |
Esophageal Carcinoma | Phase 2 | ES | 15 Jul 2020 | |
Metastatic Solid Tumor | Phase 2 | US | 15 Jul 2020 | |
Metastatic Solid Tumor | Phase 2 | DK | 15 Jul 2020 |
Phase 1/2 | 48 | (GEN1044 Doses 0.3/3/3 mg) | bedzfmotoc(oaozhmaird) = ffphhcehry skvtmtnjzt (yygposiaya, rroqemckso - vmynnojofk) View more | - | 01 Feb 2023 | ||
(GEN1044 Doses 1/3/10 mg) | bedzfmotoc(oaozhmaird) = crubtnhfpq skvtmtnjzt (yygposiaya, tfyeblyrdx - xmpfimbwcy) View more |